AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28974305 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (n = 20) with a 6-mL injection of 0.9% saline
Number of subjects: 40
Study 27358638 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise training plus diet regimen
Number of subjects: 100
Study 27358638 — intervention group
Group type: COMPARATOR
Intervention: No treatment intervention (Control)
Number of subjects: 100
Study 24002348 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 37
Study 22214287 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (stenting of the infarct-related coronary artery with abciximab as adjunct treatment)
Number of subjects: 216
Study 22214287 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 216
Study 22214287 — intervention group
Group type: COMPARATOR
Intervention: Non-viable group
Number of subjects: 216
Study 22214287 — intervention group
Group type: EXPERIMENTAL
Intervention: Viable-conservative group
Number of subjects: 216
Study 19753509 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient client-centered psychotherapy (CCP)
Number of subjects: 29
Study 19753509 — intervention group
Group type: COMPARATOR
Intervention: Guided self help (GSH)
Number of subjects: 29
Study 17331542 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 0
Study 15776131 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium 10 mg
Number of subjects: 12
Study 15776131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection distance of 2-3 cm proximally from the tumor
Number of subjects: 47
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection distance of 4-6 cm proximally from the tumor
Number of subjects: 47
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection distance of more than 6 cm proximally from the tumor
Number of subjects: 47
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy for antral tumors
Number of subjects: 47
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal resection for antral tumors
Number of subjects: 47
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal or total gastrectomy based on preoperative histology for antral tumors
Number of subjects: 47
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy for mid-third tumors
Number of subjects: 47
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy for mid-third tumors if resection distance is adequate
Number of subjects: 47
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy for proximal third tumors
Number of subjects: 47
Study 12616819 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal resections
Number of subjects: 47
Study 9797594 — intervention group
Group type: EXPERIMENTAL
Intervention: Health belief model reminder card
Number of subjects: 259
Study 9797594 — intervention group
Group type: COMPARATOR
Intervention: Usual neutrally worded card
Number of subjects: 259
Study 7662752 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation technique (autogenic training and/or music)
Number of subjects: 39
Study 7662752 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery training
Number of subjects: 39
Study 7662752 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BFB)
Number of subjects: 39
Study 2766327 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (XYL) chewing gum
Number of subjects: 28
Study 2766327 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol/Sorbitol (XYL/SOR) chewing gum
Number of subjects: 28
Study 2766327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (SOR) chewing gum
Number of subjects: 28
Study 2766327 — intervention group
Group type: COMPARATOR
Intervention: Control group (sucrose-containing gums)
Number of subjects: 28
Study 84372 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 9
Study 84372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 84372 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 9
Study 31982398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous progesterone administered intraperitoneally
Number of subjects: 0
Study 31035017 — intervention group
Group type: EXPERIMENTAL
Intervention: ARD-3150 (inhaled liposomal ciprofloxacin)
Number of subjects: 582
Study 31035017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 582
Study 27580820 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion program
Number of subjects: 613
Study 27580820 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke management programs
Number of subjects: 613
Study 25446547 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoSure device for hysteroscopic removal of polyps and myomas
Number of subjects: 118
Study 23033548 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritually based intervention
Number of subjects: 0
Study 23033548 — intervention group
Group type: COMPARATOR
Intervention: Nonspiritual comparison
Number of subjects: 0
Study 22150146 — intervention group
Group type: EXPERIMENTAL
Intervention: External fixation (Hoffmann II compact non‐bridging)
Number of subjects: 61
Study 22150146 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation (Micronail)
Number of subjects: 61
Study 19684472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix
Number of subjects: 1106
Study 19684472 — intervention group
Group type: COMPARATOR
Intervention: Gardasil
Number of subjects: 1106
Study 19684472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix and Gardasil
Number of subjects: 1106
Study 17884137 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin complex supplementation
Number of subjects: 80
Study 14681846 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g butter + 40 g alcohol + 50 g carbohydrate
Number of subjects: 11
Study 14681846 — intervention group
Group type: COMPARATOR
Intervention: 100 g butter alone
Number of subjects: 11
Study 14681846 — intervention group
Group type: COMPARATOR
Intervention: 100 g butter + 120 g carbohydrate
Number of subjects: 11
Study 11226356 — intervention group
Group type: EXPERIMENTAL
Intervention: Information about smoking, sent under signature of the subject's general practitioner, certificates and posters intended to reinforce non-smoking behaviour.
Number of subjects: 2942
Study 11226356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2942
Study 9833177 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg o.i.d. (increased to 16 mg o.i.d. if necessary)
Number of subjects: 161
Study 9833177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 7982389 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil lead abatement
Number of subjects: 0
Study 3154330 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg daily
Number of subjects: 16
Study 3154330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3154330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily
Number of subjects: 16
Study 3154330 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Nifedipine + Chlorthalidone)
Number of subjects: 16
Study 3154330 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 16
Study 31216575 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA diet enriched with oil-based margarine
Number of subjects: 83
Study 31216575 — intervention group
Group type: COMPARATOR
Intervention: SFA diet enriched with butter
Number of subjects: 83
Study 31216575 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA diet (normal-weight)
Number of subjects: 83
Study 31216575 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA diet (obese)
Number of subjects: 83
Study 31216575 — intervention group
Group type: COMPARATOR
Intervention: SFA diet (normal-weight)
Number of subjects: 83
Study 31216575 — intervention group
Group type: COMPARATOR
Intervention: SFA diet (obese)
Number of subjects: 83
Study 28718697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical disc replacement
Number of subjects: 151
Study 28718697 — intervention group
Group type: COMPARATOR
Intervention: Cervical fusion
Number of subjects: 151
Study 25259674 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER (40, 80, 120 mg/day)
Number of subjects: 0
Study 25259674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23466657 — intervention group
Group type: EXPERIMENTAL
Intervention: IPB perception with pitch change and preboundary lengthening but without the boundary pause.
Number of subjects: 0
Study 23466657 — intervention group
Group type: COMPARATOR
Intervention: IPB perception with full prosodic marking (not explicitly tested in the study but implied as a comparison).
Number of subjects: 0
Study 21220052 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer algorithm for adjudication of cardiogenic shock events
Number of subjects: 5745
Study 21220052 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer algorithm for adjudication of congestive heart failure (CHF) events
Number of subjects: 5745
Study 21220052 — intervention group
Group type: COMPARATOR
Intervention: Physician review for CHF events
Number of subjects: 5745
Study 21220052 — intervention group
Group type: COMPARATOR
Intervention: Physician review for cardiogenic shock events
Number of subjects: 5745
Study 21220052 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adjudication of suspected events
Number of subjects: 5745
Study 21220052 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to adjudication
Number of subjects: 5745
Study 21220052 — intervention group
Group type: EXPERIMENTAL
Intervention: Source document collection
Number of subjects: 5745
Study 19318651 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate‐impregnated sponge (CHGIS) dressings
Number of subjects: 1636
Study 19318651 — intervention group
Group type: COMPARATOR
Intervention: 3-day dressing changes
Number of subjects: 1636
Study 19318651 — intervention group
Group type: COMPARATOR
Intervention: 7-day dressing changes
Number of subjects: 1636
Study 16505046 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (1.0 mg/min over 50 minutes)
Number of subjects: 18
Study 16505046 — intervention group
Group type: COMPARATOR
Intervention: Histamine (0.32 microg/kg per minute over 30 minutes)
Number of subjects: 18
Study 15599834 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3540
Study 11055324 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal tea
Number of subjects: 40
Study 11055324 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 40
Study 9062618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone hydrochloride 0.05 mg/kg
Number of subjects: 10
Study 9062618 — intervention group
Group type: COMPARATOR
Intervention: Intranasal oxycodone hydrochloride 0.1 mg/kg
Number of subjects: 10
Study 8330469 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose enteric-coated aspirin (100 mg daily)
Number of subjects: 400
Study 8330469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 3777411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% methohexital solution at 20 mg/kg body wt.
Number of subjects: 223
Study 3777411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% methohexital solution at 25 mg/kg body wt.
Number of subjects: 223
Study 3777411 — intervention group
Group type: COMPARATOR
Intervention: 5% methohexital solution
Number of subjects: 223
Study 3777411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% methohexital solution
Number of subjects: 223
Study 3777411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% methohexital solution at 15 mg/kg body wt.
Number of subjects: 223
Study 3777411 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg body wt. and 10 mg/kg body wt. dosages
Number of subjects: 223
Study 29266290 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment combined with fractional CO2 laser therapy
Number of subjects: 0
Study 29266290 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 0
Study 29266290 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administration after laser irradiation
Number of subjects: 0
Study 29266290 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRP treatment)
Number of subjects: 0
Study 27130705 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone (25 mg every other day, increased to 25 mg once daily on Day 30, and to 50 mg once daily on Day 60)
Number of subjects: 1066
Study 27130705 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (2.5→5, 5→10, 7.5→15, 10→20, and 15→20 mg, uptitrated on Day 30)
Number of subjects: 1066
Study 27130705 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (10→20 mg)
Number of subjects: 1066
Study 27130705 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1066
Study 24012684 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard wording
Number of subjects: 32
Study 24012684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified wording
Number of subjects: 32
Study 24012684 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated standard wording
Number of subjects: 32
Study 24012684 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated intensified wording
Number of subjects: 32
Study 23406818 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 371
Study 23406818 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate hemodialysis (BD)
Number of subjects: 371
Study 20062969 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix‐induced autologous chondrocyte implantation (MACI)
Number of subjects: 60
Study 20062969 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 60
Study 18773341 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct method using a 24 Fr bumper-button-type device
Number of subjects: 140
Study 18773341 — intervention group
Group type: COMPARATOR
Intervention: Pull method
Number of subjects: 140
Study 18773341 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct method
Number of subjects: 140
Study 15734668 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS)
Number of subjects: 0
Study 15734668 — intervention group
Group type: COMPARATOR
Intervention: Arotinolol
Number of subjects: 0
Study 12746087 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 12746087 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 12746087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11775204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mannitolum 250 ml
Number of subjects: 68
Study 11775204 — intervention group
Group type: COMPARATOR
Intervention: Intravenous albumin 20 g
Number of subjects: 68
Study 8858219 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I (8 micrograms.kg‐1.h‐1) for 5 days by continuous subcutaneous infusion
Number of subjects: 7
Study 8858219 — intervention group
Group type: COMPARATOR
Intervention: Saline (NaCl 0.9%)
Number of subjects: 7
Study 1324011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepriston (RU 486)
Number of subjects: 1
Study 6734705 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (12, 24, 48, 96 mg)
Number of subjects: 10
Study 6734705 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (48 mg and 96 mg)
Number of subjects: 10
Study 6734705 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (given in a ratio of 3.33:1 to piretanide)
Number of subjects: 10
Study 30957673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 21
Study 30957673 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 29471100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic brain networks from functional magnetic resonance imaging (fMRI) data
Number of subjects: 1
Study 29471100 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning and functional brain networks
Number of subjects: 1
Study 26869012 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 150 mg XL for seven nights
Number of subjects: 20
Study 26869012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26869012 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 150 mg XL
Number of subjects: 20
Study 25081182 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated microsimulation model of HPV infection and cervical cancer
Number of subjects: 0
Study 25081182 — intervention group
Group type: COMPARATOR
Intervention: Control arm of the Costa Rica Vaccine Trial (2004-2010)
Number of subjects: 0
Study 22891782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood (ILIB) therapy for 1 hour daily for 15 days over 3 weeks
Number of subjects: 24
Study 22891782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood (ILIB) therapy
Number of subjects: 24
Study 22891782 — intervention group
Group type: COMPARATOR
Intervention: Sham group (ILIB with no laser power)
Number of subjects: 24
Study 20618978 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional longitudinal change
Number of subjects: 103
Study 20618978 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient perceived change
Number of subjects: 103
Study 20618978 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancy between conventional longitudinal change and patient perceived change
Number of subjects: 103
Study 19104122 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical negative pressure (TNP) wound closure using a locally constructed device
Number of subjects: 48
Study 19104122 — intervention group
Group type: COMPARATOR
Intervention: Wet-to-dry gauze dressings (control)
Number of subjects: 48
Study 16154478 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg
Number of subjects: 392
Study 16154478 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 392
Study 16154478 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 500 mg
Number of subjects: 392
Study 16154478 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 392
Study 16154478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 16154478 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (Aspirin and Acetaminophen)
Number of subjects: 392
Study 12573299 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyltestosterone (MT) 40 mg/day for 3 days, then 240 mg/day for 3 days
Number of subjects: 20
Study 12573299 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyltestosterone (MT)
Number of subjects: 20
Study 12573299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10505677 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse transcription-polymerase chain reaction (RT-PCR) with fluorogenic probes for detecting the T215Y mutation.
Number of subjects: 0
Study 7546004 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-sleep measures
Number of subjects: 56
Study 1683189 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine nasal spray (0.5 mg/mL)
Number of subjects: 56
Study 1683189 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate nasal spray (20 mg/mL)
Number of subjects: 56
Study 6793058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements (1000 iu daily)
Number of subjects: 0
Study 6793058 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupplemented)
Number of subjects: 0
Study 30929856 — intervention group
Group type: EXPERIMENTAL
Intervention: Arts-integrated science units
Number of subjects: 16
Study 30929856 — intervention group
Group type: COMPARATOR
Intervention: Traditional science instruction (control)
Number of subjects: 16
Study 28421633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulathromycin IM q 7 days (n = 80)
Number of subjects: 240
Study 28421633 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-rifampin, orally q24h (n = 80)
Number of subjects: 240
Study 28421633 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (n = 80)
Number of subjects: 240
Study 25803626 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (Lactobacillus acidophilus 10, 1 × 10(9)CFU; Lactobacillus rhamnosus HS 111, 1 × 10(9) CFU; Lactobacillus casei 10, 1 × 10(9) CFU; Bifidobacterium bifidum, 1 × 10(9)CFU; fructooligosaccharides (FOS) 100 mg), administered twice daily for 14 days
Number of subjects: 46
Study 25803626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group C)
Number of subjects: 46
Study 25803626 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 46
Study 23256143 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 (ergocalciferol)
Number of subjects: 52
Study 23256143 — intervention group
Group type: EXPERIMENTAL
Intervention: D3 (cholecalciferol)
Number of subjects: 52
Study 21076316 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk reduction intervention (16 weeks) including 150 minutes of regular exercise per week, 200-300 kcal reduced daily diet, one-on-one psychobehavioral counseling, and telephone coaching
Number of subjects: 43
Study 21076316 — intervention group
Group type: COMPARATOR
Intervention: Control group received a booklet with basic diabetic education
Number of subjects: 43
Study 19784816 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day for 6 months
Number of subjects: 72
Study 17258855 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg OD
Number of subjects: 62
Study 17258855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg OD
Number of subjects: 62
Study 17258855 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alfuzosin and sildenafil
Number of subjects: 62